TaiwanJ Pharmaceuticals Co., Ltd.

TPEX:6549 Stock Report

Market Cap: NT$746.7m

TaiwanJ Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

TaiwanJ Pharmaceuticals has been growing earnings at an average annual rate of 12.3%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been declining at an average rate of 24.5% per year.

Key information

12.3%

Earnings growth rate

15.1%

EPS growth rate

Biotechs Industry Growth12.2%
Revenue growth rate-24.5%
Return on equity-48.4%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Companies Like TaiwanJ Pharmaceuticals (GTSM:6549) Are In A Position To Invest In Growth

Apr 14
Companies Like TaiwanJ Pharmaceuticals (GTSM:6549) Are In A Position To Invest In Growth

Will TaiwanJ Pharmaceuticals (GTSM:6549) Spend Its Cash Wisely?

Dec 29
Will TaiwanJ Pharmaceuticals (GTSM:6549) Spend Its Cash Wisely?

Revenue & Expenses Breakdown

How TaiwanJ Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:6549 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-281616
31 Mar 2411-171615
31 Dec 2323-61514
30 Sep 2330-382012
30 Jun 2338-712510
31 Mar 2327-822511
31 Dec 2215-922413
30 Sep 228-601815
30 Jun 221-271217
31 Mar 2211-201317
31 Dec 2122-121418
30 Sep 2122-141419
30 Jun 2122-151520
31 Mar 2111-291523
31 Dec 200-421426
30 Sep 200-471634
30 Jun 200-511742
31 Mar 2031-282034
31 Dec 1962-52226
30 Sep 1962-762129
30 Jun 1962-1472131
31 Mar 1931-1932061
31 Dec 180-2382091
30 Sep 180-19520112
30 Jun 180-15220132
31 Mar 180-16921149
31 Dec 170-18621166
30 Sep 170-21022191
30 Jun 170-23424215
31 Mar 170-22825209
31 Dec 160-22325202
30 Sep 160-19925182
30 Jun 160-17625161
31 Mar 160-15924146
31 Dec 150-14222132
30 Sep 150-12824109
30 Jun 150-1142587
31 Mar 150-1062480
31 Dec 140-982373

Quality Earnings: 6549 is currently unprofitable.

Growing Profit Margin: 6549 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 6549 is unprofitable, but has reduced losses over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare 6549's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6549 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.8%).


Return on Equity

High ROE: 6549 has a negative Return on Equity (-48.39%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies